scholarly journals To Evaluate Anti-HLA Antibodies Sensitization in Pre- and Post-renal Transplant Patient’s Serum: A Retrospective Case Series

2019 ◽  
pp. e000187
Author(s):  
Nishtha Agarwal ◽  
Sanjeev Goswami
Keyword(s):  
Acute Rejection ◽  
De Novo ◽  
Solid Phase ◽  
Case Series ◽  
Antibody Detection ◽  
Unrelated Donor ◽  
Retrospective Case ◽  
Post Transplant ◽  
Financial Condition ◽  
Hla Antibody

Introduction: In India, patients of renal failure are dependent on live related or unrelated donor. Because of poor financial condition patients do not go for DSA (Donor Specific Antibody) detection using Luminex. In absence of screening of de-novo production of DSA and don’t get proper management. As a result of which patient undergo acute rejection. Case Series: Here we are presenting 5 acute rejection cases comparing there DSA in pre-transplant and post-transplant sera using solid-phase assays.5 renal transplanted patients undergone acute and hyperacute rejection (Banff's classification) were considered for presented case series. Collected serum (pre and post-transplant on day of rejection) from each patient was subjected to detection of anti-HLA antibody using Luminex-PRA. Conclusion: Presence of donor-specific anti-HLA antibody with their titer was detected in pre and post-transplant serum. It is found that the strength of DSA is directly proportional to graft life.

HLA Antibody Detection and Characterization by Solid Phase Immunoassays: Methods and Pitfalls

2012 ◽  
pp. 289-308 ◽  
Author(s):  
Andrea A. Zachary ◽  
Renato M. Vega ◽  
Donna P. Lucas ◽  
Mary S. Leffell
Keyword(s):  
Solid Phase ◽  
Antibody Detection ◽  
Hla Antibody

scholarly journals Caveats of HLA antibody detection by solid‐phase assays

2019 ◽  
Vol 33 (1) ◽  
pp. 18-29 ◽  
Author(s):  
Caroline Wehmeier ◽  
Gideon Hönger ◽  
Stefan Schaub
Keyword(s):  
Solid Phase ◽  
Antibody Detection ◽  
Hla Antibody

7-P: Inter-laboratory comparison of HLA antibody detection by solid phase methods

2009 ◽  
Vol 70 ◽  
pp. S15
Author(s):  
Deborah O. Crowe ◽  
Sallyanne C. Fossey
Keyword(s):  
Solid Phase ◽  
Antibody Detection ◽  
Hla Antibody

Solid phase HLA antibody detection technology - challenges in interpretation

2010 ◽  
Author(s):  
B. D. Tait ◽  
F. Hudson ◽  
G. Brewin ◽  
L. Cantwell ◽  
R. Holdsworth
Keyword(s):  
Solid Phase ◽  
Antibody Detection ◽  
Detection Technology ◽  
Hla Antibody

scholarly journals Post-transplant Lymphoproliferative Disorders: Single Center Case Series and Literature Review

2020 ◽  
pp. 1-6
Author(s):  
Sumayyah Altamimi ◽  
◽  
Mohamed Al Shuaibi ◽  
Mohamed Alnahdi ◽  
Abdulrahman Altheaby ◽  
...  
Keyword(s):  
De Novo ◽  
Organ Transplant ◽  
Tumor Development ◽  
Case Series ◽  
Standard Of Care ◽  
Lymphoproliferative Disorders ◽  
Outcome Analysis ◽  
Solid Organ ◽  
Hematopoietic Stem ◽  
Post Transplant

Post-transplant lymphoproliferative disorders (PTLD) are referred to lymphoid and/or plasmacytic proliferation which occur as result of immunosuppression therapy in patient underwent solid organ or allogeneic hematopoietic stem cell transplantation. Among solid organ transplant recipients, it accounts approximately 20% of all cancers. Epstein-Barr virus (EBV) has been linked to the pathogenesis of PTLD when EBV was identified in the tumor biopsies. In most affected patients, PTLD occurs as a result of proliferation of EBV positive B cell following immunosuppression and impaired Tcell immune activity. EBV negative PTLD has been documented but no clear etiology has been confirmed, however theories of previous exposure to EBV which is completely cleared at the time of PTLD is diagnosed, different viruses or chronic antigenic stimulation all been considered as provoking factors for tumor development. Clinical symptomatology at presentation of patients with PTLD is usually indistinct from de novo lymphoproliferative disorders and chemotherapy protocols in this group of patients are generally similar to the standard of care of lymphoma treatment according to the subtype in addition to cessation or dose reduction of immunosuppressive therapy. We report our experience and outcome analysis in PTLD management among 23 patients from our institution treated between 2011 and 2019.

scholarly journals Who Needs Surgical Stabilization for Pyogenic Spondylodiscitis? Retrospective Analysis of Non-Surgically Treated Patients

2021 ◽  
pp. 219256822110394
Author(s):  
Ronen Blecher ◽  
Sven Frieler ◽  
Bilal Qutteineh ◽  
Clifford A. Pierre ◽  
Emre Yilmaz ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Conservative Treatment ◽  
De Novo ◽  
Vertebral Osteomyelitis ◽  
Case Series ◽  
Spinal Instability ◽  
Radiographic Outcome ◽  
Retrospective Case ◽  
Posterior Element ◽  
Non Surgical Treatment

Study Design: Retrospective case series analysis. Objective: To identify relevant clinical and radiographic markers for patients presenting with infectious spondylo-discitis associated with spinal instability directly related to the infectious process. Methods: We evaluated patients presenting with de-novo intervertebral discitis or vertebral osteomyelitis /discitis (VOD) who initiated non-surgical treatment. Patients who failed conservative treatment and required stabilization surgery within 90 days were defined as “ failed treatment group” (FTG). Patients who experienced an uneventful course served as controls and were labeled as “ nonsurgical group” (NSG). A wide array of baseline clinical and radiographic parameters was retrieved and compared between 2 groups. Results: Overall 35 patients had initiated non-surgical treatment for VOD. 25 patients had an uneventful course (NSG), while 10 patients failed conservative treatment (“FTG”) within 90 days. Factors found to be associated with poorer outcome were intra-venous drug abuse (IVDA) as well as the presence of fever upon initial presentation. Radiographically, involvement of the same-level facets and the extent of caudal and rostral VB involvement in both MRI and CT were found to be significantly associated with poorer clinical and radiographic outcome. Conclusions: We show that clinical factors such as IVDA status and fever as well as the extent of osseous and posterior element involvement may prove to be helpful in favoring surgical treatment early on in the management of spinal infections.

scholarly journals Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation

2018 ◽  
Vol 29 (7) ◽  
pp. 1979-1991 ◽  
Author(s):  
Julio Pascual ◽  
Stefan P. Berger ◽  
Oliver Witzke ◽  
Helio Tedesco ◽  
Shamkant Mulgaonkar ◽  
...  
Keyword(s):  
Acute Rejection ◽  
Confidence Interval ◽  
Kidney Transplant ◽  
Calcineurin Inhibitor ◽  
De Novo ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Post Transplant ◽  
Antibody Mediated Rejection ◽  
End Point

Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recipients to receive, in combination with induction therapy and corticosteroids, everolimus with reduced-exposure CNI (everolimus arm) or mycophenolic acid (MPA) with standard-exposure CNI (MPA arm). The primary end point was treated biopsy-proven acute rejection or eGFR<50 ml/min per 1.73 m2 at post-transplant month 12 using a 10% noninferiority margin.Results In the intent-to-treat population (everolimus n=1022, MPA n=1015), the primary end point incidence was 48.2% (493) with everolimus and 45.1% (457) with MPA (difference 3.2%; 95% confidence interval, −1.3% to 7.6%). Similar between-treatment differences in incidence were observed in the subgroups of patients who received tacrolimus or cyclosporine. Treated biopsy-proven acute rejection, graft loss, or death at post-transplant month 12 occurred in 14.9% and 12.5% of patients treated with everolimus and MPA, respectively (difference 2.3%; 95% confidence interval, −1.7% to 6.4%). De novo donor-specific antibody incidence at 12 months and antibody-mediated rejection rate did not differ between arms. Cytomegalovirus (3.6% versus 13.3%) and BK virus infections (4.3% versus 8.0%) were less frequent in the everolimus arm than in the MPA arm. Overall, 23.0% and 11.9% of patients treated with everolimus and MPA, respectively, discontinued the study drug because of adverse events.Conclusions In kidney transplant recipients at mild-to-moderate immunologic risk, everolimus was noninferior to MPA for a binary composite end point assessing immunosuppressive efficacy and preservation of graft function.

De Novo Sustained Refractory Status Epilepticus and Encephalopathy: A Retrospective Case Series

2010 ◽  
Vol 25 (12) ◽  
pp. 1535-1538 ◽  
Author(s):  
Joanna S. Fong ◽  
Stephen Hantus ◽  
Ebru Erbayat Altay ◽  
Ingrid Tuxhorn
Keyword(s):  
Status Epilepticus ◽  
De Novo ◽  
Case Series ◽  
Refractory Status Epilepticus ◽  
Retrospective Case ◽  
Refractory Status ◽  
Retrospective Case Series
Sign in / Sign up

Export Citation Format

Share Document